A patent applicant’s misconduct during the prosecution of a patent can render the patent unenforceable under the doctrine of “inequitable conduct.” A recent U.S. Court of Appeals for the Federal Circuit decision, Regeneron Pharmaceuticals v. Merus, potentially extends that doctrine to encompass misconduct during patent-infringement litigation, rather than just during patent prosecution. See No. 2016-1346, 2017 WL 3184400 (Fed. Cir. July 27, 2017). We report here on the Regeneron case and other cases addressing whether litigation misconduct can render a patent unenforceable, and provide guidance for practitioners.
Inequitable Conduct
Inequitable conduct is an equitable defense to patent infringement, and a powerful one: a finding of inequitable conduct as to a single claim of a patent renders all claims of that patent unenforceable. Therasense v. Becton, Dickinson and Co., 649 F.3d 1276, 1289-90 (Fed. Cir. 2011). Inequitable conduct can also “spill over” to render unenforceable other patents within the same patent family. And it can lead to antitrust and unfair competition claims by competitors and consumers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
